# Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients

> **NCT05825443** · PHASE2 · RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 57 (estimated)

## Conditions studied

- Immunotherapy
- Chemotherapy

## Interventions

- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT05825443
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-10
- **Primary completion:** 2026-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2023-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05825443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05825443, "Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05825443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*